317 related articles for article (PubMed ID: 10394568)
1. [Mortality in a cohort of intravenous drug users before the introduction of potent HIV therapy].
Muga R; Egea JM; Navío M; Sirera G; Vall M; Tor J
Med Clin (Barc); 1999 May; 112(19):721-5. PubMed ID: 10394568
[TBL] [Abstract][Full Text] [Related]
2. Effect of education on overall and cause-specific mortality in injecting drug users, according to HIV and introduction of HAART.
Jarrin I; Lumbreras B; Ferreros I; Pérez-Hoyos S; Hurtado I; Hernández-Aguado I
Int J Epidemiol; 2007 Feb; 36(1):187-94. PubMed ID: 17085455
[TBL] [Abstract][Full Text] [Related]
3. The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and non-infected injecting drug users.
Ferreros I; Lumbreras B; Hurtado I; Pérez-Hoyos S; Hernández-Aguado I
Addiction; 2008 Apr; 103(4):651-9. PubMed ID: 18339110
[TBL] [Abstract][Full Text] [Related]
4. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001.
García de la Hera M; Ferreros I; del Amo J; García de Olalla P; Pérez Hoyos S; Muga R; del Romero J; Guerrero R; Hernández-Aguado I;
J Epidemiol Community Health; 2004 Nov; 58(11):944-50. PubMed ID: 15483312
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver.
Spittal PM; Craib KJ; Wood E; Laliberté N; Li K; Tyndall MW; O'Shaughnessy MV; Schechter MT
CMAJ; 2002 Apr; 166(7):894-9. PubMed ID: 11949985
[TBL] [Abstract][Full Text] [Related]
6. [Mortality and causes of death among intravenous drug addicts in Oslo].
Eskild A; Magnus P; Samuelsen SO; Sohlberg C; Kittelsen P
Tidsskr Nor Laegeforen; 1993 Apr; 113(11):1331-3. PubMed ID: 8337619
[TBL] [Abstract][Full Text] [Related]
7. [Risk reduction and intravenous drug use abstinence in patients with HIV infection. The SEROCO group].
Meyer L; Wade A; Persoz A; Boué F; Dellamonica P; Caroli-Bosc C; Carré N
Rev Epidemiol Sante Publique; 1998 Feb; 46(1):34-9. PubMed ID: 9533232
[TBL] [Abstract][Full Text] [Related]
8. Mortality is influenced by locality in a major HIV/AIDS epidemic.
Druyts EF; Rachlis BS; Lima VD; Harvard SS; Zhang W; Brandson EK; Strathdee SA; Montaner JS; Hogg RS
HIV Med; 2009 May; 10(5):274-81. PubMed ID: 19210694
[TBL] [Abstract][Full Text] [Related]
9. Changing patterns in causes of death in a cohort of injecting drug users, 1980-2001.
Copeland L; Budd J; Robertson JR; Elton RA
Arch Intern Med; 2004 Jun; 164(11):1214-20. PubMed ID: 15197047
[TBL] [Abstract][Full Text] [Related]
10. [An 1-year prospective cohort study on mortality of injecting drug users].
Zhang L; Ruan YH; Jiang ZQ; Yang ZN; Liu SZ; Zhou F; He YX; Yin L; Qin GM; Shao YM
Zhonghua Liu Xing Bing Xue Za Zhi; 2005 Mar; 26(3):190-3. PubMed ID: 15941506
[TBL] [Abstract][Full Text] [Related]
11. Mortality among injecting drug users in Melbourne: a 16-year follow-up of the Victorian Injecting Cohort Study (VICS).
Stoové MA; Dietze PM; Aitken CK; Jolley D
Drug Alcohol Depend; 2008 Aug; 96(3):281-5. PubMed ID: 18434044
[TBL] [Abstract][Full Text] [Related]
12. Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, Md.
Nelson KE; Vlahov D; Solomon L; Cohn S; Muñoz A
Arch Intern Med; 1995 Jun; 155(12):1305-11. PubMed ID: 7778962
[TBL] [Abstract][Full Text] [Related]
13. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
14. [The incidence of human immunodeficiency virus type-1 (HIV-1) infection in parenteral drug users].
Aviñó Rico MJ; Hernández Aguado I; Pérez Hoyos S; García de la Hera M; Ruiz I; Bolumar Montrull F
Med Clin (Barc); 1994 Mar; 102(10):369-73. PubMed ID: 8182982
[TBL] [Abstract][Full Text] [Related]
15. Predictors of mortality among injecting and non-injecting HIV-negative drug users in northern Thailand.
Quan VM; Vongchak T; Jittiwutikarn J; Kawichai S; Srirak N; Wiboonnatakul K; Razak MH; Suriyanon V; Celentano DD
Addiction; 2007 Mar; 102(3):441-6. PubMed ID: 17298652
[TBL] [Abstract][Full Text] [Related]
16. Impact of injecting drug use on mortality in Danish HIV-infected patients: a nation-wide population-based cohort study.
Larsen MV; Omland LH; Gerstoft J; Larsen CS; Jensen J; Obel N; Kronborg G
Addiction; 2010 Mar; 105(3):529-35. PubMed ID: 20402997
[TBL] [Abstract][Full Text] [Related]
17. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
[TBL] [Abstract][Full Text] [Related]
18. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
19. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain.
Brugal MT; Domingo-Salvany A; Puig R; Barrio G; García de Olalla P; de la Fuente L
Addiction; 2005 Jul; 100(7):981-9. PubMed ID: 15955014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
